Altria Short Sellers Retreat as Yield Premium Holds Firm

Altria Group enters September with one of its more constructive setups of the year — shorts are exiting at pace, the borrow market is effectively wide open, and options positioning has normalised from an elevated defensive stance seen just weeks ago.

The sharpest move in the data is in short interest. Bears have cut exposure aggressively. Short interest has fallen 23% over the past month, dropping from above 55 million shares to just over 40 million, now representing 2.4% of the free float. That is a low reading by any measure — and the retreat appears deliberate. Between early August and late August, daily short share counts shed roughly 15 million shares, the bulk of the unwind concentrated in the first two weeks of the month. The ORTEX short score has tracked the move lower, easing from 38.3 in mid-August to 36.3 now, placing MO in a relatively uncrowded position among its sector peers.

The borrow market confirms there is nothing structurally pressuring the remaining shorts. Availability is extraordinarily loose — over 5,100% of short interest is covered by shares still available to lend, comfortably above the 52-week low of around 1,494%, and meaningfully above even the recently expanded supply seen through July. Cost to borrow is a near-irrelevant 0.46%, fractionally off its recent range and far below any level that would burden a short thesis financially. The options market tells a similarly quiet story. The put/call ratio is running at 1.05, essentially in line with its 20-day average of 1.06, with a z-score of -0.10 — completely flat. Contrast that with early August, when the PCR was running above 1.27 for several consecutive sessions; that defensive hedging has largely unwound as the stock recovered.

The Street sits at a genuine impasse. Barclays maintained its Underweight rating and cut its price target to $58 on August 11 — the most recent analyst action in the data, and one that sits well below the current price of $69.57. UBS, on the other side, carries a Buy with a $79 target, and Bank of America holds a Buy at $73. The mean target is $70, barely above current levels, suggesting the consensus is essentially neutral on near-term upside. Bulls lean on Marlboro's dominant 42% U.S. cigarette market share and the On! oral tobacco brand's 8.8% retail share — up 180 basis points year-on-year. Bears counter that combustible volume declines are structural, with fewer than 15% of adults reporting recent cigarette use. The dividend factor score ranks in the 99th percentile, reinforcing MO's identity as a yield instrument rather than a growth trade; the 12-month forward EPS growth score is solid at the 76th percentile, but EPS momentum over both 30 and 90 days sits in the mid-40s. The EV/EBITDA of roughly 10x has compressed modestly over the past 30 days, consistent with the recent price drift.

Peer performance this week adds some texture. PM slid 3.5% over the week, a meaningful divergence from MO's 2.2% gain. BATS and UVV posted modest gains of around 1% and 0.5% respectively, while IMB added 1.2%. MO's outperformance relative to PM in particular is notable given how closely the two have historically tracked — the divergence may reflect MO's domestic yield premium commanding more attention in the current rate environment.

Earnings are the natural next focus, with the next print scheduled for October 29. The most recent quarter — reported July 30 — saw the stock fall 8.8% in a single session and 9.6% over five days, a sharp reaction that likely explains some of the defensive put positioning seen in early August. Whether the October print can reverse that pattern, and whether the Street's Barclays-versus-UBS divide narrows ahead of results, are the two markers worth tracking through the rest of September.